• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    NRC Health Announces Second Quarter 2025 Results

    7/28/25 5:00:00 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $NRC alert in real time by email

    Reports third consecutive quarter of sequential TRCV Growth

    National Research Corporation, dba NRC Health, (NASDAQ:NRC) today announced results for the second quarter 2025.

    CEO Statement

    Trent S. Green, Chief Executive Officer of NRC Health, commented: "We're encouraged by our second-quarter results, which demonstrate continued momentum across key areas of our business. In my early weeks as CEO, I've been energized by feedback from both current and prospective customers, particularly their enthusiasm for our product portfolio and appreciation for the service mindset of our associates. To provide additional context on the quarter, we're reinstating our quarterly earnings call, which I hope investors will join tomorrow, July 29, at 10 a.m. ET."

    Additional Information

    Total recurring contract value1, or TRCV, grew 2% sequentially, the third consecutive quarter of TRCV growth and the highest sequential growth rate since the first quarter of 2021. New logo sales, cross-sells, and customer retention have improved over the last several quarters, attributable to a stronger sales team, a product portfolio that resonates in the marketplace, and the strength of our customer service organization.

    With the transition from founder-led leadership, compensation arrangements for executive leaders were implemented to preserve philosophical and economic alignment with long-term shareholders. These arrangements, primarily non-recurring cash bonuses and equity grants, resulted in a net margin of 0% for the second quarter. Excluding these items, adjusted EBITDA margin2 was 30% in the quarter and has remained relatively stable over the past year due to cost control initiatives and higher revenue per FTE.

    Dividends and Stock Repurchases

    The Company's Board of Directors on July 23, 2025, declared a quarterly cash dividend of $0.12 (twelve cents) per share payable Friday, October 10, 2025, to shareholders of record as of the close of business on Friday, September 26, 2025.

    During the second quarter, NRC repurchased 381,736 shares at a weighted average price of $14.96 per share. During 2025, the company has returned a total of $16.1 million to shareholders through dividends and stock repurchases.

    1 Total recurring contract value (TRCV) is a measure of projected revenue under all renewable contracts for the next 12-month period.

    2 Adjusted EBITDA is a non-GAAP financial measure. A reconciliation of adjusted EBITDA to net income and disclosure regarding why we believe adjusted EBITDA provides useful information to investors is included later in this release.

    Earnings Call Information

    The company will be hosting an earnings call to provide additional detail on the quarter on July 29, 2025, 10 a.m. ET, available at nrchealth.com/investor-relations.

    About NRC Health

    For more than 40 years, NRC Health (NASDAQ:NRC) has led the charge to humanize healthcare and support organizations in their understanding of each unique individual. NRC Health's commitment to Human Understanding® helps leading healthcare systems get to know each person they serve not as point-in-time insights, but as an ongoing relationship. Guided by its uniquely empathic heritage, NRC Health's patient-focused approach, unmatched market research, and emphasis on consumer preferences are transforming the healthcare experience, creating strong outcomes for patients and entire healthcare systems. For more information, email [email protected], or visit www.nrchealth.com.

    Non-GAAP Performance Measures

    The company prepares its financial statements and presents its financial results in accordance with U.S. GAAP. However, it also provides additional non-GAAP financial information related to specific items management believes to be important in the evaluation of its operating results and performance. Reconciliations of GAAP to non-GAAP financial information, and a discussion of why the company believes providing this additional information is useful to investors, is provided in the "Non-GAAP Disclosures" section below.

    Forward-Looking Statements

    This press release contains certain statements that may be considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such statements are subject to the safe harbor created by those sections and the Private Securities Litigation Reform Act of 1995, as amended. Such statements may be identified by their use of terms or phrases such as "believes," "expect," "focus," "potential," "will," derivations thereof, and similar terms and phrases. In this press release, the statements related to future dividends, share repurchases, and revenue are forward-looking statements. Forward-looking statements are based upon the current beliefs and expectations of our management and are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, which could cause future events and actual results to differ materially from those set forth in, contemplated by, or underlying the forward-looking statements, including those risks and uncertainties as set forth in the Risk Factors section of our Annual Report on Form 10-K for the year ended December 31, 2024, and various disclosures in our press releases, stockholder reports, and other filings with the Securities and Exchange Commission. We disclaim any obligation to update or revise any forward-looking statements to reflect actual results or changes in the factors affecting the forward-looking information.

    NATIONAL RESEARCH CORPORATION AND SUBSIDIARY

    Unaudited Condensed Consolidated Statements of Income

    (In thousands, except per share data)

     

     

     

    Three months ended

    June 30

     

     

    Six months ended

    June 30

     

     

     

    2025

     

     

    2024

     

     

    2025

     

     

    2024

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Revenue

     

    $

    34,038

     

     

    $

    35,021

     

     

    $

    67,588

     

     

    $

    70,334

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Operating expenses:

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Direct

     

     

    12,974

     

     

     

    13,422

     

     

     

    26,031

     

     

     

    27,278

     

    Selling, general and administrative

     

     

    17,734

     

     

     

    11,221

     

     

     

    28,089

     

     

     

    22,471

     

    Depreciation and amortization

     

     

    1,742

     

     

     

    1,513

     

     

     

    3,284

     

     

     

    2,960

     

    Total operating expenses

     

     

    32,450

     

     

     

    26,156

     

     

     

    57,404

     

     

     

    52,709

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Operating income

     

     

    1,588

     

     

     

    8,865

     

     

     

    10,184

     

     

     

    17,625

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Other income (expense):

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Interest income

     

     

    21

     

     

     

    25

     

     

     

    41

     

     

     

    69

     

    Interest expense

     

     

    (1,032

    )

     

     

    (555

    )

     

     

    (1,932

    )

     

     

    (1,160

    )

    Other, net

     

     

    4

     

     

     

    (11

    )

     

     

    11

     

     

     

    (16

    )

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Total other expense

     

     

    (1,007

    )

     

     

    (541

    )

     

     

    (1,880

    )

     

     

    (1,107

    )

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Income before income taxes

     

     

    581

     

     

     

    8,324

     

     

     

    8,304

     

     

     

    16,518

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Provision for income taxes

     

     

    687

     

     

     

    2,149

     

     

     

    2,623

     

     

     

    3,984

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Net income (loss)

     

    $

    (106

    )

     

    $

    6,175

     

     

    $

    5,681

     

     

    $

    12,534

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Earnings (loss) Per Share of Common Stock:

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Basic Earnings (loss) Per Share

     

    $

    (0.01

    )

     

    $

    0.26

     

     

    $

    0.25

     

     

    $

    0.53

     

    Diluted Earnings (loss) Per Share

     

    $

    (0.01

    )

     

    $

    0.26

     

     

    $

    0.25

     

     

    $

    0.52

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Weighted average shares and share equivalents outstanding:

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Basic

     

     

    22,658

     

     

     

    23,871

     

     

     

    22,814

     

     

     

    23,870

     

    Diluted

     

     

    22,658

     

     

     

    23,915

     

     

     

    22,820

     

     

     

    23,934

     

    NATIONAL RESEARCH CORPORATION AND SUBSIDIARY

    Unaudited Condensed Consolidated Balance Sheets

    (Dollars in thousands, except share amounts and par value)

     

     

     

    June 30,

    2025

     

     

    December 31,

    2024

     

    Assets

     

     

     

     

     

     

     

     

    Current assets:

     

     

     

     

     

     

     

     

    Cash and cash equivalents

     

    $

    5,274

     

     

    $

    4,233

     

    Accounts receivable, net

     

     

    12,416

     

     

     

    11,054

     

    Other current assets

     

     

    7,630

     

     

     

    4,313

     

    Total current assets

     

     

    25,320

     

     

     

    19,600

     

     

     

     

     

     

     

     

     

     

    Property and equipment, net

     

     

    42,232

     

     

     

    38,269

     

    Goodwill

     

     

    66,152

     

     

     

    66,152

     

    Other, net

     

     

    7,683

     

     

     

    8,518

     

    Total assets

     

    $

    141,387

     

     

    $

    132,539

     

     

     

     

     

     

     

     

     

     

    Liabilities and Shareholders' Equity

     

     

     

     

     

     

     

     

    Current liabilities:

     

     

     

     

     

     

     

     

    Current portion of notes payable, net of unamortized debt issuance costs

     

    $

    3,928

     

     

    $

    4,789

     

    Accounts payable and accrued expenses

     

     

    6,794

     

     

     

    6,285

     

    Accrued compensation

     

     

    5,685

     

     

     

    4,774

     

    Deferred revenue

     

     

    15,603

     

     

     

    15,786

     

    Dividends payable

     

     

    2,776

     

     

     

    2,770

     

    Other current liabilities

     

     

    1,140

     

     

     

    1,454

     

    Total current liabilities

     

     

    35,926

     

     

     

    35,858

     

     

     

     

     

     

     

     

     

     

    Notes payable, net of current portion and unamortized debt issuance costs

     

     

    77,029

     

     

     

    57,895

     

    Other non-current liabilities

     

     

    7,104

     

     

     

    7,502

     

    Total liabilities

     

     

    120,059

     

     

     

    101,255

     

     

     

     

     

     

     

     

     

     

    Shareholders' equity:

     

     

     

     

     

     

     

     

    Preferred stock, $0.01 par value, authorized 2,000,000 shares, none issued

     

     

    --

     

     

     

    --

     

    Common stock, $0.001 par value; authorized 110,000,000 shares, issued 31,782,158 in 2025 and 31,072,144 in 2024, outstanding 23,103,685 in 2025 and 23,083,116 in 2024

     

     

    32

     

     

     

    31

     

    Additional paid-in capital

     

     

    180,858

     

     

     

    180,249

     

    Retained earnings (accumulated deficit)

     

     

    (16,894

    )

     

     

    (17,064

    )

    Treasury stock

     

     

    (142,668

    )

     

     

    (131,932

    )

    Total shareholders' equity

     

    $

    21,328

     

     

    $

    31,284

     

    Total liabilities and shareholders' equity

     

    $

    141,387

     

     

    $

    132,539

     

    Non- GAAP Measures of Financial Performance

    In addition to consolidated GAAP financial measures, NRC Health reviews various non-GAAP financial measures, including "Adjusted EBITDA," "Adjusted Net Income," and "Adjusted Earnings per Share." NRC Health believes Adjusted EBITDA, Adjusted Net Income and Adjusted Earnings per Share are helpful supplemental measures to assist management and investors in evaluating the Company's operating results as (i) they exclude certain items that are unusual in nature or whose fluctuation from period to period do not necessarily correspond to changes in the operations of NRC Health's business, and (ii) the exclusion of non-cash stock compensation is useful for investors applying certain valuation metrics and is consistent with the leverage ratio for our credit facility. Adjusted EBITDA represents net income before interest, taxes, depreciation, amortization and certain non-recurring executive compensation and non-cash stock compensation items. Adjusted Net Income represents net income adjusted to add back certain non-recurring executive compensation and non-cash stock compensation and the related tax. There is no comprehensive, authoritative guidance for the presentation of such non-GAAP information, which is only meant to supplement GAAP results by providing additional information that management utilizes to assess performance.

    Reconciliation of GAAP Net Income (Loss) to Adjusted Net Income

    (In thousands, except per share data, unaudited)

     

     

     

    Three months ended

    June 30

     

     

    Six months ended

    June 30

     

     

     

    2025

     

     

    2024

     

     

    2025

     

     

    2024

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Net income (loss)

     

    $

    (106

    )

     

    $

    6,175

     

     

    $

    5,681

     

     

    $

    12,534

     

    Add back:

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Non-recurring executive compensation

     

     

    6,640

     

     

     

    -

     

     

     

    6,640

     

     

     

    -

     

    Tax on non-recurring executive compensation

     

     

    (468

    )

     

     

    -

     

     

     

    (468

    )

     

     

    -

     

    Non-cash stock compensation

     

     

    307

     

     

     

    (57

    )

     

     

    478

     

     

     

    (92

    )

    Tax on stock compensation

     

     

    -

     

     

     

    14

     

     

     

    -

     

     

     

    23

     

    Adjusted Net Income

     

    $

    6,373

     

     

    $

    6,132

     

     

    $

    12,331

     

     

    $

    12,465

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Earnings (loss) Per Share of Common Stock:

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Basic Earnings (loss) Per Share

     

    $

    (0.01)

     

     

    $

    0.26

     

     

    $

    0.25

     

     

    $

    0.52

     

    Diluted Earnings (loss) Per Share

     

    $

    (0.01)

     

     

    $

    0.26

     

     

    $

    0.25

     

     

    $

    0.52

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Adjusted Earnings (loss) Per Share of Common Stock:

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Adjusted Basic Earnings (loss) Per Share

     

    $

    0.28

     

     

    $

    0.26

     

     

    $

    0.54

     

     

    $

    0.52

     

    Adjusted Diluted Earnings (loss) Per Share

     

    $

    0.28

     

     

    $

    0.26

     

     

    $

    0.54

     

     

    $

    0.52

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Weighted average shares and share equivalents outstanding:

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Basic

     

     

    22,658

     

     

     

    23,871

     

     

     

    22,814

     

     

     

    23,870

     

    Diluted

     

     

    22,658

     

     

     

    23,915

     

     

     

    22,820

     

     

     

    23,934

     

    Reconciliation of GAAP Net Income (Loss) to Adjusted EBITDA

    Unaudited

    (In thousands, except per share data)

     

     

     

    Three months ended

     

     

    June 30,

    2025

     

     

    March 31,

    2025

     

     

    December 31,

    2024

     

     

    September 30,

    2024

     

     

    June 30,

    2024

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Revenue

     

    $

    34,038

     

     

    $

    33,551

     

     

    $

    36,907

     

     

    $

    35,819

     

     

    $

    35,021

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Net income (loss)

     

    $

    (106

    )

     

    $

    5,787

     

     

    $

    6,561

     

     

    $

    5,688

     

     

    $

    6,175

     

    Add back

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Interest expense

     

     

    1,032

     

     

     

    899

     

     

     

    729

     

     

     

    706

     

     

     

    555

     

    Income taxes

     

     

    687

     

     

     

    1,936

     

     

     

    2,315

     

     

     

    1,608

     

     

     

    2,149

     

    Depreciation and amortization

     

     

    1,742

     

     

     

    1,542

     

     

     

    1,516

     

     

     

    1,546

     

     

     

    1,513

     

    Non-recurring executive compensation

     

     

    6,640

     

     

     

    -

     

     

     

    -

     

     

     

    -

     

     

     

    -

     

    Non-cash stock compensation

     

     

    307

     

     

     

    171

     

     

     

    188

     

     

     

    189

     

     

     

    (57

    )

    Adjusted EBITDA

     

    $

    10,302

     

     

    $

    10,335

     

     

    $

    11,309

     

     

    $

    9,737

     

     

    $

    10,335

     

    Adjusted EBITDA Margin

     

     

    30.3%

     

     

     

    30.8%

     

     

     

    30.6%

     

     

     

    27.2%

     

     

     

    29.5%

     

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250728115594/en/

    NRC Health Investor Relations Contact

    [email protected]

    Get the next $NRC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NRC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NRC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Accounting Officer Freeman Jordan Nicole bought $10,000 worth of shares (771 units at $12.97) (SEC Form 4)

    4 - NATIONAL RESEARCH CORP (0000070487) (Issuer)

    8/4/25 4:40:44 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Large owner Beans Patrick E bought $33,974 worth of shares (2,500 units at $13.59), increasing direct ownership by 8% to 35,003 units (SEC Form 4)

    4 - NATIONAL RESEARCH CORP (0000070487) (Issuer)

    5/13/25 11:30:22 AM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $NRC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NRC Health Partners with Mosaic Life Care to Advance Patient Experience Across the Midwest

    Mosaic Life Care, a physician-led health system located in northwest Missouri, announced a new partnership with NRC Health, the leader in healthcare experience management. Together, the organizations will work to elevate patient and employee experience across Mosaic's system, reinforcing its vision for Mosaic to be the region's first choice and most trusted partner in healthcare. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251202915784/en/Mosaic Life Care, a physician-led health system located in northwest Missouri, announced a new partnership with NRC Health, the leader in healthcare experience management. Together, the organ

    12/2/25 9:00:00 AM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    NRC Health Appoints David Burik as Executive Vice President, Strategic Insights

    Seasoned healthcare strategy leader to advance The Governance Institute and Market Insights NRC Health, the leader in healthcare experience management, today announced the appointment of David Burik as Executive Vice President, Strategic Insights, effective January 5, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251120531393/en/NRC Health, the leader in healthcare experience management, today announced the appointment of David Burik as Executive Vice President, Strategic Insights, effective January 5, 2026. David joins NRC Health from Guidehouse, where he has served as partner and leader of the Center for Health Insigh

    11/20/25 9:00:00 AM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    NRC Health Partners with BJC HealthCare to Advance Experience Excellence Across a Unified Network

    NRC Health, the leader in healthcare experience management, is proud to announce a new partnership with BJC Health System, one of the nation's largest nonprofit integrated healthcare delivery organizations. The collaboration will unify and elevate patient and employee experiences across BJC's hospitals, clinics, and academic partners, reinforcing its mission to improve the health and well-being of the people and communities it serves through leadership, education, innovation, and excellence in medicine. Through this partnership, NRC Health will provide its Patient Experience, Leader, and Employee Rounding solutions—creating a consistent, data-driven foundation for improvement and connecti

    11/13/25 9:00:00 AM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $NRC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Rau Jason Russell

    3 - NATIONAL RESEARCH CORP (0000070487) (Issuer)

    11/6/25 5:01:46 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 4 filed by Director Nunnelly John N

    4 - NATIONAL RESEARCH CORP (0000070487) (Issuer)

    10/21/25 7:20:15 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 4 filed by Director Wheeler Penny Ann

    4 - NATIONAL RESEARCH CORP (0000070487) (Issuer)

    10/21/25 7:18:01 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $NRC
    SEC Filings

    View All

    SEC Form 10-Q filed by National Research Corporation

    10-Q - NATIONAL RESEARCH CORP (0000070487) (Filer)

    11/7/25 1:03:21 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    National Research Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - NATIONAL RESEARCH CORP (0000070487) (Filer)

    10/27/25 5:03:13 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    National Research Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - NATIONAL RESEARCH CORP (0000070487) (Filer)

    8/28/25 4:09:44 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $NRC
    Leadership Updates

    Live Leadership Updates

    View All

    NRC Health Appoints David Burik as Executive Vice President, Strategic Insights

    Seasoned healthcare strategy leader to advance The Governance Institute and Market Insights NRC Health, the leader in healthcare experience management, today announced the appointment of David Burik as Executive Vice President, Strategic Insights, effective January 5, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251120531393/en/NRC Health, the leader in healthcare experience management, today announced the appointment of David Burik as Executive Vice President, Strategic Insights, effective January 5, 2026. David joins NRC Health from Guidehouse, where he has served as partner and leader of the Center for Health Insigh

    11/20/25 9:00:00 AM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    NRC Health Announces Shane Harrison as Chief Financial Officer

    National Research Corporation (NASDAQ:NRC), doing business as NRC Health, a publicly-traded leader in healthcare experience, is pleased to announce the appointment of Shane Harrison as its incoming Executive Vice President and Chief Financial Officer, effective on or about September 25, 2025. Chief Financial Officer Shane Harrison is a seasoned finance leader with more than 25 years of experience spanning corporate finance, investor relations, and strategic transactions. He most recently served as Senior Vice President – Finance and Investor Relations at PowerSchool, a leading K-12 education SaaS provider, since 2022. Prior to that, he served as Senior Vice President – Corporate Develop

    8/28/25 8:00:00 AM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    National Research Corporation Appoints Trent Green as Chief Executive Officer

    National Research Corporation (NASDAQ:NRC), doing business as NRC Health, a publicly-traded leader in healthcare improvement, is pleased to announce the appointment of Trent Green as its incoming Chief Executive Officer, effective June 1, 2025. Green will succeed Mike Hays, the company's current CEO, who will transition to the role of Chairman, ensuring a smooth leadership transition while maintaining NRC Health's mission-driven and shareholder-focused approach. Green brings more than 25 years of healthcare leadership experience, most recently serving as CEO of One Medical, San Francisco, CA, and previously as Chief Operating Officer at Legacy Health, Portland, OR. His expertise in care de

    3/4/25 4:01:00 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $NRC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by National Research Corporation

    SC 13G/A - NATIONAL RESEARCH CORP (0000070487) (Subject)

    11/13/24 4:05:19 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13G/A filed by National Research Corporation (Amendment)

    SC 13G/A - NATIONAL RESEARCH CORP (0000070487) (Subject)

    3/8/24 4:05:05 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13D/A filed by National Research Corporation (Amendment)

    SC 13D/A - NATIONAL RESEARCH CORP (0000070487) (Subject)

    3/5/24 4:31:31 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $NRC
    Financials

    Live finance-specific insights

    View All

    NRC Health Announces Third Quarter 2025 Results

     Third quarter TRCV* increased 8% year-over-year to $141.7 million Cash flow from operations increased 46% year-over-year to $13.8 million National Research Corporation, dba NRC Health, (NASDAQ:NRC), a leader in healthcare experience improvement solutions, today announced results for the third quarter 2025. "We delivered our fourth consecutive quarter of recurring contract value growth, driven by strong sales and meaningful improvement in customer retention," said Trent Green, CEO of NRC Health. "This sustained momentum reflects how our solutions deliver insights, engagement, and enablement that help healthcare organizations better understand, anticipate, and respond to the experience

    10/27/25 5:00:00 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    NRC Health Announces Second Quarter 2025 Results

    Reports third consecutive quarter of sequential TRCV Growth National Research Corporation, dba NRC Health, (NASDAQ:NRC) today announced results for the second quarter 2025. CEO Statement Trent S. Green, Chief Executive Officer of NRC Health, commented: "We're encouraged by our second-quarter results, which demonstrate continued momentum across key areas of our business. In my early weeks as CEO, I've been energized by feedback from both current and prospective customers, particularly their enthusiasm for our product portfolio and appreciation for the service mindset of our associates. To provide additional context on the quarter, we're reinstating our quarterly earnings call, which I

    7/28/25 5:00:00 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    NRC Health Announces First Quarter Results

    National Research Corporation, dba NRC Health, (NASDAQ:NRC) today announced results for the first quarter 2025 and other corporate developments. Highlights: Total Recurring Value Contract Value Increases Sequentially Sales Force Expansion Accelerates New Share Repurchase Program Announced Operating Expenses Decline Dividend Declared Overview Michael D. Hays, Chief Executive Officer of NRC Health, commented on the Company's performance and recent developments: "The key milestone this quarter was a second consecutive quarter of sequential increase in total recurring contract value, which remains the leading indicator of revenue growth. This progress reflects the rebuilding of o

    4/28/25 5:00:00 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care